Autres langues Alaunos Therapeutics, Inc.

Actions

TCRT

US98973P3091

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 17:17:11 14/08/2026			Varia. 5j.	Varia. 1 janv.
1,955 ^USD	-1,76 %		-1,26 %	-39,16 %

29/06	Alaunos Therapeutics publie de nouvelles données précliniques sur l'ALN1003 montrant une réduction du poids du foie après ajustement du taux de graisse corporelle dans une étude de 48 jours sur des souris DIO	CI
26/05	Alaunos Therapeutics fait état d'une amélioration métabolique globale avec l'ALN1003 dans des études sur des souris obèses	CI

Autres langues

29/06	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study
29/06	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
26/05	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
26/05	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
18/05	Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models
18/05	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
18/05	Alaunos Therapeutics Announces Updated Preclinical Data For ALN1003
15/05	Ziopharm: Q1 Earnings Snapshot
15/05	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
01/04	Ziopharm: Q4 Earnings Snapshot
31/03	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Alaunos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
05/03	Price Adrian Issues a Letter to Alaunos Therapeutics Inc
02/03	Alaunos Therapeutics, Inc. Announces Early Data from Two Non-Good Laboratory Practice Diet-Induced Obesity Mouse Studies Evaluating ALN1003
02/03	Alaunos Therapeutics announces positive preclinical proof-of-concept data for ALN1003, a differentiated non-hormonal oral treatment for obesity and related metabolic disorders
02/03	Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
24/02	Price Adrian Issues a Letter to Alaunos Therapeutics Inc
08/01	Alaunos Therapeutics terminates engagement with Cantor Fitzgerald
05/12	Price Adrian Issues a Letter to Alaunos Therapeutics Inc
14/11	Ziopharm: Q3 Earnings Snapshot
14/11	Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
31/10/25	Price Adrian Engages with Alaunos Therapeutics Inc
30/10/25	Price Adrian Engages with Alaunos Therapeutics Inc
21/08/25	Alaunos Therapeutics Inc files for mixed shelf of up to $50 million - SEC filing
15/08/25	Ziopharm: Q2 Earnings Snapshot